Highest-materiality recent filing
AIP completes acquisition of Avanos for $1.272B; stockholders receive $25.00/share cash
Deal valued at ~$1.272B; Avanos stockholders get $25.00 per share in cash.
Avanos stockholders approve $25/share acquisition by American Industrial Partners
99.75% of votes cast in favor, representing ~74.96% of outstanding shares.
Avanos supplements proxy with additional M&A details amid stockholder lawsuits; merger on track
Two stockholder lawsuits filed June 29-30, 2026 in NY Supreme Court seeking to enjoin merger; demand letters also received alleging proxy deficiencies.
Avanos receives all regulatory approvals for AIP acquisition; closing expected by July 27
All required regulatory approvals received for acquisition by American Industrial Partners affiliates.
Avanos Medical announces Q1 2026 results; filing includes no financial figures
Press release issued May 5, 2026 covering three months ended March 31, 2026.
Avanos Medical to be acquired by AIP for $25/share, $1.272B enterprise value
Avanos stockholders receive $25.00 per share in cash; enterprise value approx. $1.272B.
Avnos Medical raises CEO David Pacitti's annual LTIP target to $5.5M from $5M
Board increased CEO David Pacitti's annual LTIP target from $5M to $5.5M.
Avanos adds two directors in cooperation deal with activist Radoff
James Cunniff (CEO of Electromed) and William Burke (former EVP/CFO Haemonetics) nominated for board at 2026 annual meeting.
Avanos reports Q4 adjusted EPS $0.29 vs $0.43 prior year; FY2025 sales $701.2M up 1.9%
Q4 net sales $180.9M (+0.7% YoY); SNS segment up 8.7% to $115.1M; PM&R up 1.3% to $61.6M.
Avanos Medical presents at JP Morgan Healthcare Conference; no material financial updates disclosed
CEO Dave Pacitti presented company strategy at JP Morgan Healthcare Conference on January 13, 2026.
Avanos eliminates CCO and GC roles; final severance includes full vesting of James's 16,300 RSUs
Company eliminated Chief Commercial Officer and General Counsel positions effective Dec 1, 2025 as part of restructuring.
Avanos Medical files Q3 2025 earnings release; detailed results not provided in filing text
Press release for three and nine months ended September 30, 2025 furnished as Exhibit 99.1.
Kerr Holbrook (CCO) and Mojirade James (General Counsel & Secretary) terminated effective Dec 1, 2025 due to position elimination in restructuring.
Avanos Medical acquires Nexus Medical for TKO anti-reflux connector; accretive to revenue/ EPS
Acquisition of Nexus Medical, LLC, maker of TKO needleless connector technology for NICU/PICU.
Avanos Q2 net loss $76.8M, goodwill impairment $77M; HA divestiture completed July 31
Q2 net sales $175M (+1.9% YoY); net loss $76.8M vs $4.3M income a year ago.
Avanos Q1 EPS $0.14, adjusted EPS $0.26; cuts 2025 adj. EPS view to $0.75-$0.95 on tariffs
Net sales $167.5M (+0.8% YoY); organic net sales up 2.8%.
Avanos Medical finalizes separation with Officer Greiner; $2.1M severance, accelerated RSUs
Cash severance of $2.1M plus prorated 2025 bonus based on actual performance, paid in 2026.
Avanos appoints Jason Pickett as Interim CFO; Greiner departs with $2.1M severance
Michael Greiner departs after not being offered comparable role post-interim CEO; receives $2.1M severance, prorated bonus, $50K consulting fee.
All five director nominees elected with 85.8% to 90.3% of votes cast; broker non-votes excluded.
Avanos appoints David Pacitti as CEO, effective April 14, 2025; compensation disclosed
David Pacitti, former Siemens Healthineers Americas President, becomes CEO effective April 14, 2025.
Avanos CFO transition: Greiner departs, Pickett named Interim CFO
Michael Greiner leaves Avanos effective April 18, 2025; receives $2.1M severance, prorated 2025 bonus, and 6 months COBRA.
Avanos Medical names David Pacitti as CEO, effective April 14, 2025
David Pacitti appointed CEO of Avanos Medical, effective April 14, 2025.
Avanos Medical reports Q4 and FY2024 results; specific figures not available in filing excerpt
Press release dated February 26, 2025 for the three months and year ended December 31, 2024.
Avanos Medical at JP Morgan conference; no specific financial metrics disclosed in available text
Presentation by Interim CEO Michael Greiner at 43rd Annual JP Morgan Healthcare Conference on January 13, 2025.
Avanos Medical formalizes Interim CFO consulting agreement with Warren Machan through May 2025
Warren Machan appointed Interim CFO effective Oct 28, 2024; consulting agreement formalized Dec 2, 2024.
Avanos Medical authorizes new $25M share repurchase program
Board approved up to $25.0 million in common stock repurchases over one year.
CEO Joseph Woody retires; CFO Michael Greiner named interim CEO; Warren Machan interim CFO
Joseph Woody retired as CEO and board member effective Oct 28, 2024; will consult through Apr 30, 2025 at $84,618/month.
Avanos Medical reports Q2 2024 results; filing lacks detailed financials
Results announced for three and six months ended June 30, 2024.
Avanos Medical appoints Indrani Franchini to Board of Directors, effective July 1, 2024
Appointment fills a vacancy; Franchini will serve on Audit and Compliance Committees.
Avanos appoints Sigfrido Delgado as SVP, Integrated Supply Chain
Sigfrido (Sig) Delgado named Senior Vice President, Integrated Supply Chain, effective May 13, 2024.
Avanos Medical reports Q1 2024 results; key figures not available in 8-K
Company announced results for three months ended March 31, 2024.
Avanos Medical stockholders elect all five director nominees, ratify auditor, approve say-on-pay
Elected directors: Gary Blackford, Lisa Egbuonu-Davis, Patrick O'Leary, Julie Shimer, Joseph Woody; each received over 39M votes for.
Q4 net sales $173.3M (-4.6% YoY); full-year net sales $673.3M (-1.6%) on lower HA sales.
Avanos Medical issues preliminary Q4/FY2023 results; no figures in filing
Announced selected unaudited preliminary results for Q4 and full year ended Dec 31, 2023.
Avanos Medical reports Q3 2023 results; no financial details available in filing text
Filed 8-K on Nov 1, 2023 announcing Q3 earnings results for period ended Sept 30, 2023.
Avanos closes sale of Respiratory Health business to SunMed for $110M cash
Divestiture of Avanos' Respiratory Health business closed Oct 2, 2023; $110M cash purchase price subject to adjustments for indebtedness, inventory, and chargebacks.
Avanos Q2 sales $169.4M, adjusted EPS $0.24; FY2023 adjusted EPS guidance $1.05-$1.15
Q2 net sales $169.4M (-0.9% YoY); net loss $4.3M vs net income $4.8M a year ago.
Avanos clarifies Q2 2023 results beat consensus after third-party error
Third party incorrectly reported Avanos missed consensus; total sales including discontinued RH business were $199.8M.
Avanos Medical authorizes $25M share repurchase program
Board approved $25M one-year share repurchase program on July 28, 2023.
Avanos Medical agrees to acquire Diros Technology, RF pain management portfolio strengthened
Deal includes all outstanding shares of Diros Technology; financial terms not disclosed.
Avanos sells Respiratory Health to SunMed for $110M, accelerates portfolio focus
Definitive agreement to sell substantially all RH assets for $110M cash; close expected late 2023.
Avanos Medical reports Q1 results and holds annual meeting; all proposals approved
Q1 2023 earnings released May 3, 2023; no financial figures provided in the filing.
Avanos Medical appoints Dr. Lisa Egbuonu-Davis to board of directors
Dr. Egbuonu-Davis appointed as independent director effective March 6, 2023; serves on Compliance and Governance Committees.
Cash expenses of $20M-$25M for transformation: $9M-$12M consulting/retention, $8M-$11M manufacturing/supply chain.
Filing reports results for three months and year ended December 31, 2022.
Avanos Medical amends CEO severance to 2.5x pay; SVP International resigns
CEO severance payout multiple increased from 2x to 2.5x on qualified termination.
Three-year plan: combine Chronic Care & Pain franchises, exit low-margin products, cost management, and focused M&A.
Avanos appoints Sudhakar Varshney as SVP Global Supply Chain and Procurement
Sudhakar Varshney appointed as Senior Vice President, Global Supply Chain and Procurement.
Avanos Medical reports Q3 2022 earnings; no specific data provided in filing excerpt
Quarter ended September 30, 2022 results disclosed on November 2, 2022.
Director Maria Sainz to resign from Avanos Board effective Jan 1, 2023
Director Maria Sainz notified Avanos of resignation from Board, effective January 1, 2023.
On April 28, 2025, Avanos Medical, Inc. (the “Company”) and Michael C. Greiner entered into a Separation and Consulting Agreement (the “Separation and Consulting Agreement”).
Mr. Machan no longer serves as the Company’s Interim Chief Financial Officer effective April 14, 2025
On April 18, 2025, Michael C. Greiner announced that he will leave the Company to pursue other opportunities because the Company did not offer him a position comparable to the one he held prior to his role as the Company’s Interim Chief Executive Officer.
The Company has appointed Jason M. Pickett as Interim Chief Financial Officer and Treasurer, effective April 14, 2025.
On March 17, 2025, Avanos Medical, Inc. (the “Company”) announced the appointment of David Pacitti as the Company’s Chief Executive Officer, effective April 14, 2025.
Mr. Machan no longer serves as the Company’s Interim Chief Financial Officer effective April 14, 2025
The Company has appointed Jason M. Pickett as Interim Chief Financial Officer and Treasurer, effective April 14, 2025.
On April 18, 2025, Michael C. Greiner announced that he will leave Avanos Medical, Inc. (the “Company”) to pursue other opportunities because the Company did not offer him a position comparable to the one he held prior to his role as the Company’s Interim Chief Executive Officer.
On March 17, 2025, Avanos Medical, Inc. (the “Company”) announced the appointment of David Pacitti as the Company’s Chief Executive Officer, effective April 14, 2025.
the Company appointed Michael C. Greiner to serve as Interim Chief Executive Officer of the Company.
On October 28, 2024, the Company announced the retirement of Joseph F. Woody as Chief Executive Officer and a member of the Board of Directors of the Company, effective immediately.
On June 28, 2024, the Board of Directors (the “Board”) of Avanos Medical, Inc. (the “Company”) appointed Indrani Franchini to the Board, effective July 1, 2024.
Max materiality 1.00 · Median 0.50 · Most common event leadership